 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | European Research Centre for Drug Discovery and Development - UNISI |
| Street 1: | via aldo moro 2 |
| Street 2: | |
| City: | Siena |
| Province: | Siena |
| Post Code: | 53100 |
| Country: | Italy |
| Phone: | +390577234172 |
| Email: | campiani@unisi.it |
| Web Site: | http://www.natsyndrugs.org |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | Technical agencies |
| Organization Type - Primary: | Academic / Research Institution |
| Organization Type - Secondary: | None |
| Is your organization legally registered in your country: | Yes |
| Organization Reach: | International |
| Organization Description: | |
| The European Research Centre for Drug Discovery & Development (www.natsyndrugs.org) is an EU network created in 2003 to promote drug development research in the field of infectious diseases and others. NatSynDrugs is the acronym of the European Research Centre for Drug Discovery and Development, an international multidisciplinary research network that encompasses Universities and Institutes that have a major commitment to the development of innovative drugs. NatSynDrugs is constituted by core groups who have the knowledge and skills for each stage of drug development: from basic molecular research through proof-of-principle to pre-clinical testing. Each research group contributes complementary skills to the Centre to facilitate a complete drug development programme. NatSynDrugs since 2003 activated several research programmes and social networking activities in collaboration with EU. Viral infections and malaria are well established research fields in the Centre while just 2 years ago we started a large programme for the development of novel antitubercular agents. Skills and experience of NatSynDrugs researchers in drug development may lead to the identification of innovative drugs against TB through a close collaboration with partners at StopTB. In particular we are interested in Drug resistance and translating research from bench to bedside. |
|
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 11 - 25 |
| Number of part-time staff who are directly involved with TB: | 1 - 5 |
| Number of volunteers who are directly involved with TB: | 0 |
| What is your organization's annual budget (USD) dedicated to TB? | $10,001-$25,000 |
| How did you hear about the Stop TB Partnership: | Internet search |
| Why do you wish join the Stop TB Partnership: | Involvement in Stop TB Working Groups |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | No |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| We are working on novel targets for the control of TB infection | |
Geographical Reach | |
| Which country is your headquarters located in: | Italy |
| Which WHO region is the main focus of your work: | Global |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Italy |
Specializations | |
|
Research and Development |
Specializations in Countries | |
| Research and Development | Italy |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
New TB Drugs: We are working on novel targets in order to develop potential drug candidates with innovative mechanisms of action able to combat the TB infection. One of our research topics is the development of inhibitors of the enzyme Zmp1, that is involved in the inhibition of inflammasome activation. We are also studying, through computational techniques and synthesis of specific ligands, the enzymes RpfB and RipA which are involved in the virulence of the Mycobacterium within the host. |
|
Declaration | |
| Declaration of interests: No conflicts of interest were delacred. | |
| Application date: | June 11, 2010 |
| Last updated: | June 25, 2012 |